clinical trial · NCT04929236
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Octapharma·phase3·recruiting·n = 30
Pediatric Chronic Inflammatory Demyelinating PolyneuropathyPanzyga
brief summary
Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
started
Oct 1, 2023
primary completion
Jun 1, 2026
completion
Jun 1, 2026
last updated
Jun 6, 2025
official title
Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol